Regency Capital Management Inc.\De Ocuphire Pharma, Inc. Transaction History

Regency Capital Management Inc.\De

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 05, 2022	SELL	$2.75 - $4.39 $0 - $0	0 Closed	0 $0
Q4 2021 Feb 03, 2022	SELL	$3.4 - $5.19 $51,000 - $77,850	-15,000 Closed	0 $0
Q2 2021 Jul 07, 2021	SELL	$4.24 - $6.57 $8,480 - $13,140	-2,000 Reduced 11.76%	15,000 $79,000
Q1 2021 May 25, 2021	BUY	$5.7 - $13.31 $96,900 - $226,270	17,000 New	17,000 $99,000

2.55M

14.1K

800

Ticker OCUP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,579,800
Market Cap $21.8M
Description
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...

Get notified when there are updates to the investment portfolio of Regency Capital Management Inc.\De, based on Form 13F filings with the SEC.

Stay updated on Regency Capital Management Inc.\De with notifications on news.